Why the study?
Does short-term pantoprazole added to aspirin and clopidogrel affect gastrointestinal bleeding or MACE in patients with acute STEMI undergoing PCI?
Does short-term pantoprazole added to aspirin and clopidogrel affect gastrointestinal bleeding or MACE in patients with acute STEMI undergoing PCI?
Short-term pantoprazole added to DAPT in STEMI patients post-PCI did not increase MACE, though the abstract contains contradictory statements regarding its efficacy in reducing gastrointestinal bleeding.
Short-term pantoprazole with DAPT appears safe in STEMI without raising MACEs; leaves open confirmation in larger trials while supporting GI protection.
The aim of the present study was to determine the effects of the short-term application of pantoprazole on the co-treatment of acute ST-segment elevation myocardial infarction (STEMI) with aspirin and clopidogrel. A total of 207 acute patients showing primary symptoms of STEMI, who received successful emergent percutaneous coronary intervention treatment during hospitalization were randomly divided into two groups. In the test group proton pump inhibitors (PPIs), the patients were treated with a combination of aspirin and clopidogrel and pantoprazole, while those in the control group were treated only with aspirin and clopidogrel. Gastrointestinal bleeding events and major adverse cardiac events (MACEs) were observed in the two groups. Gastrointestinal bleeding events of the two groups mostly occurred within the first week of hospitalization, although the incidence in the PPIs group was significantly higher than that in the control group (p<0.05). However, no significant difference was observed for the incidence of MACEs between the two groups (p>0.05). In conclusion, the results of the present study have shown that the short-term application of pantoprazole combined with aspirin and clopidogrel does not increase the incidence of MACEs in patients with acute STEMI, reduces the risk of gastrointestinal bleeding, and is thus worth promoting clinically, particularly for high-risk groups.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: